Literature DB >> 3416285

Risk of nonocular cancer among retinoblastoma patients and their parents. A population-based study in Denmark, 1943-1984.

J Winther1, J H Olsen, P de Nully Brown.   

Abstract

The risk of nonocular cancer among survivors of retinoblastoma has been investigated in a population-based study in Denmark, 1943 to 1984. None of the survivors had been treated with chemotherapeutic drugs. Forty-eight patients were treated with x-rays, and 102 patients were treated primarily with surgical removal of the eye(s). The overall relative risk (RR) for a new primary cancer was 4.2 (95% confidence limits, 1.1-11.5). In the subgroup of genetic retinoblastoma the risk was 15.4 (95% confidence limits, 2.6-50.8) and in the group of nonhereditary cancer the risk was 1.7 (95% confidence limits, 0.1-8.5). For all retinoblastoma patients the RR of bone cancer was 100 (95% confidence limits, 17-330). Parents not having retinoblastoma themselves were not at increased risk for nonocular cancer.

Entities:  

Mesh:

Year:  1988        PMID: 3416285     DOI: 10.1002/1097-0142(19881001)62:7<1458::aid-cncr2820620735>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Risk of nonocular cancer in first-degree relatives of retinoblastoma patients.

Authors:  J H Olsen; J Winther; P N Brown
Journal:  Hum Genet       Date:  1990-08       Impact factor: 4.132

Review 2.  Retinoblastoma: a review.

Authors:  I Malkani; R P Warrier; L C Yu; D L Ode
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

3.  Existing data sources for clinical epidemiology: Danish registries for studies of medical genetic diseases.

Authors:  Mary Nguyen-Nielsen; Elisabeth Svensson; Ida Vogel; Vera Ehrenstein; Lone Sunde
Journal:  Clin Epidemiol       Date:  2013-08-08       Impact factor: 4.790

4.  Incidence and Mortality of Second Primary Cancers in Danish Patients With Retinoblastoma, 1943-2013.

Authors:  Pernille A Gregersen; Maja H Olsen; Steen F Urbak; Mikkel Funding; Susanne O Dalton; Jens Overgaard; Jan Alsner
Journal:  JAMA Netw Open       Date:  2020-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.